Letrozole
- Generic Name
- Letrozole
- Brand Names
- Femara, Kisqali Femara Co-pack
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11N5
- CAS Number
- 112809-51-5
- Unique Ingredient Identifier
- 7LKK855W8I
- Background
Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.
Letrozole was granted FDA approval on 25 July 1997.
- Indication
Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...
- Associated Conditions
- Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Region Örebro County
- Target Recruit Count
- 3832
- Registration Number
- NCT06223698
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
🇸🇪University Hospital of Umeå, Umeå, Sweden
🇸🇪Akademiska University Hospital Uppsala, Uppsala, Sweden
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Conditions
- Locally Advanced Unresectable HER2-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Locally Advanced Unresectable Hormone Receptor-Positive Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
- Interventions
- Drug: AbemaciclibDrug: AnastrozoleProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Diagnostic ImagingDrug: ExemestaneOther: Fludeoxyglucose F-18Drug: Fluorine F 18 Fluoro Furanyl NorprogesteroneDrug: FulvestrantBiological: Gonadotropin-releasing Hormone AnalogDrug: LetrozoleProcedure: Positron Emission TomographyDrug: TamoxifenDrug: Therapeutic Estradiol
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 60
- Registration Number
- NCT06179303
- Locations
- 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Mridula George, MD
- Target Recruit Count
- 15
- Registration Number
- NCT06139107
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced Breast CancerMetastatic Breast CancerHormone-receptor-positive Breast CancerHormone Receptor Positive Breast CarcinomaHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerNon-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 79
- Registration Number
- NCT06120283
- Locations
- 🇺🇸
Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
🇦🇺Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 400
- Registration Number
- NCT06075953
- Locations
- 🇺🇸
Berkeley Outpatient Center, Berkeley, California, United States
🇺🇸UCSF, San Francisco, California, United States
🇺🇸Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Verastem, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT06072781
- Locations
- 🇺🇸
Texas Oncology Central, Austin, Texas, United States
🇺🇸Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Olema Pharmaceuticals, Inc.
- Target Recruit Count
- 510
- Registration Number
- NCT06016738
- Locations
- 🇬🇧
Clinical Trial Site, London, United Kingdom
🇲🇾Clinical Trials Site, Sungai Petani, Kedah, Malaysia
The Effectiveness of the Letrozole-induced Endometrial Preparation Protocol in Frozen-thawed Embryo Transfer (FET)
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2023-08-23
- Target Recruit Count
- 858
- Registration Number
- NCT06006091
- Locations
- 🇨🇳
Yu Xiao, Shanghai, China
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 90
- Registration Number
- NCT06001762
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Eastern Maine Medical Center (Northern Light), Brewer, Maine, United States
🇺🇸New England Cancer Specialists, Scarborough, Maine, United States
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5500
- Registration Number
- NCT05952557
- Locations
- 🇬🇧
Research Site, Whitchurch, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.